This is a preview of subscription content, log in via an institution to check access.
Reference
Barberio B, et al. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Clinical and Translational Gastroenterology 11: e00177, No. 5, May 2020. Available from: URL: http://doi.org/10.14309/ctg.0000000000000177
Rights and permissions
About this article
Cite this article
Adalimumab/infliximab. Reactions Weekly 1860, 21 (2021). https://doi.org/10.1007/s40278-021-97476-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-97476-2